Search Results

There are 11078 results for: content related to: Factor VIII assay mimicking in vivo coagulation conditions

  1. Anti-factor VIII antibodies in brothers with haemophilia A share similar characteristics


    J. Kahle, A. Orlowski, D. Stichel, J. F. Healey, E. T. Parker, S. M. Donfield, J. Astermark, E. Berntorp, P. Lollar, D. Schwabe and C. Königs

    Version of Record online : 8 NOV 2016, DOI: 10.1111/hae.13105

  2. You have free access to this content
    New predictive approaches for ITI treatment


    Volume 20, Issue s6, September 2014, Pages: 27–43, G. D. Minno, E. Santagostino, K. Pratt and C. Königs

    Version of Record online : 26 JUN 2014, DOI: 10.1111/hae.12467

  3. Activation, activity and inactivation of factor VIII in factor VIII products


    Volume 22, Issue 3, May 2016, Pages: 462–473, T. Orfeo, R. Elsman, M. Gissel, K. G. Mann and S. Butenas

    Version of Record online : 29 JAN 2016, DOI: 10.1111/hae.12872

  4. You have free access to this content
    Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development


    Volume 20, Issue s6, September 2014, Pages: 2–16, P. M. Mannucci, Q. Shi, S. Bonanad and R. Klamroth

    Version of Record online : 26 JUN 2014, DOI: 10.1111/hae.12465

    Corrected by:

    Erratum: Erratum

    Vol. 20, Issue 5, e376, Version of Record online: 28 AUG 2014

  5. Predictive immunogenicity of Refacto®AF


    Volume 20, Issue 4, July 2014, Pages: 486–492, S. Delignat, Y. Repessé, L. Gilardin, J. D. Dimitrov, Y.C. Lone, S. V. Kaveri and S. Lacroix-Desmazes

    Version of Record online : 30 DEC 2013, DOI: 10.1111/hae.12348

  6. Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A


    Volume 21, Issue 3, May 2015, Pages: 343–350, S. Kepa, B. Horvath, S. Reitter-Pfoertner, M. Schemper, P. Quehenberger, M. Grundbichler, M. Heistinger, P. Neumeister, C. Mannhalter and I. Pabinger

    Version of Record online : 13 JAN 2015, DOI: 10.1111/hae.12592

  7. You have free access to this content
    Third Åland islands conference on von Willebrand disease, 26–28 September 2012: meeting report


    Volume 19, Issue s3, March 2013, Pages: 1–18, E. Berntorp, B. Fuchs, M. Makris, R. Montgomery, V. Flood, J. S. O'Donnell, A. B. Federici, D. Lillicrap, P. James, U. Budde, M. Morfini, P. Petrini, S. Austin, C. Kannicht, V. Jiménez-Yuste and C. Lee

    Version of Record online : 6 FEB 2013, DOI: 10.1111/hae.12078

  8. Diagnosis and management challenges in patients with mild haemophilia A and discrepant FVIII measurements


    Volume 20, Issue 4, July 2014, Pages: 550–558, M. Trossaert, A. Lienhart, C. Nougier, M. Fretigny, M. Sigaud, S. Meunier, M. Fouassier, C. Ternisien, C. Negrier and Y. Dargaud

    Version of Record online : 12 FEB 2014, DOI: 10.1111/hae.12381

  9. Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors


    Volume 20, Issue 1, January 2014, Pages: e7–e14, H. Luna-Záizar, C. P. Beltrán-Miranda, M. A. Esparza-Flores, J. Soto-Padilla, A. Bergés-García, M. D. C. Rodríguez-Zepeda, M. T. Pompa-Garza and A. R. Jaloma-Cruz

    Version of Record online : 20 DEC 2013, DOI: 10.1111/hae.12309

  10. You have full text access to this OnlineOpen article
    Lack of recombinant factor VIII B-domain induces phospholipid vesicle aggregation: implications for the immunogenicity of factor VIII


    Volume 20, Issue 5, September 2014, Pages: 723–731, K. Grushin, J. Miller, D. Dalm, E. T. Parker, J. F. Healey, P. Lollar and S. Stoilova-McPhie

    Version of Record online : 21 APR 2014, DOI: 10.1111/hae.12421

  11. You have full text access to this OnlineOpen article
    Native plasma-derived FVIII/VWF complex has lower sensitivity to FVIII inhibitors than the combination of isolated FVIII and VWF proteins. Impact on Bethesda assay titration of FVIII inhibitors


    Volume 20, Issue 6, November 2014, Pages: 905–911, M. I. Bravo, B. Da Rocha-Souto, S. Grancha and J. I. Jorquera

    Version of Record online : 25 AUG 2014, DOI: 10.1111/hae.12494

  12. Achievements, challenges and unmet needs for haemophilia patients with inhibitors


    Volume 22, Issue S1, January 2016, Pages: 1–24, Y. Dargaud, A. Pavlova, S. Lacroix-Desmazes, K. Fischer, M. Soucie, S. Claeyssens, D.w. Scott, R. d'Oiron, G. Lavigne-Lissalde, G. Kenet, C. Escuriola Ettingshausen, A. Borel-Derlon, T. Lambert, G. Pasta and C. Négrier

    Version of Record online : 5 JAN 2016, DOI: 10.1111/hae.12860

  13. In vitro characterization of recombinant factor VIII concentrates reveals significant differences in protein content, activity and thrombin activation profile


    Volume 19, Issue 3, May 2013, Pages: 392–398, S. Pahl, A. Pavlova, J. Driesen, J. Müller, B. Pötzsch and J. Oldenburg

    Version of Record online : 18 DEC 2012, DOI: 10.1111/hae.12076

  14. Non-genetic risk factors in haemophilia A inhibitor management – the danger theory and the use of animal models


    Volume 22, Issue 5, September 2016, Pages: 657–666, K. M. Lövgren, H. Søndergaard, S. Skov and B. Wiinberg

    Version of Record online : 26 AUG 2016, DOI: 10.1111/hae.13075

  15. Usefulness of an in vitro cellular expression model for haemophilia A carrier diagnosis: illustration with five novel mutations in the F8 gene in women with isolated factor VIII:C deficiency


    Volume 21, Issue 3, May 2015, Pages: e202–e209, O. Roualdes, C. Nougier, M. Fretigny, E. Talagrand, B. Durand, C. Negrier and C. Vinciguerra

    Version of Record online : 24 FEB 2015, DOI: 10.1111/hae.12651

  16. von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo


    Volume 19, Issue 4, July 2013, Pages: 539–545, L. Tang, L. Leong, D. Sim, E. Ho, J.-M. Gu, D. Schneider, R. I. Feldman, F. Monteclaro, H. Jiang and J. E. Murphy

    Version of Record online : 28 MAR 2013, DOI: 10.1111/hae.12116

  17. You have full text access to this OnlineOpen article
    A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE


    Volume 22, Issue 6, November 2016, Pages: 957–965, P. L. Turecek, S. Romeder-Finger, C. Apostol, A. Bauer, A. Crocker-Buqué, D. A. Burger, R. Schall and H. Gritsch

    Version of Record online : 28 JUN 2016, DOI: 10.1111/hae.13001

  18. Optimization of the thrombin generation test components to measure potency of factor VIII concentrates


    Volume 22, Issue 5, September 2016, Pages: 780–789, N. K. Jha, S. A. Shestopal, M. J. Gourley, S. A. Woodle, Y. Liang, A. G. Sarafanov, M. Weinstein and M. V. Ovanesov

    Version of Record online : 1 APR 2016, DOI: 10.1111/hae.12943

  19. You have free access to this content
    Mild hemophilia A patient with novel Pro1809Leu mutation develops an anti-C2 antibody inhibiting allogeneic but not autologous factor VIII activity

    Journal of Thrombosis and Haemostasis

    Volume 13, Issue 10, October 2015, Pages: 1843–1853, K. Yada, K. Nogami, M. Takeyama, K. Ogiwara, H. Wakabayashi and M. Shima

    Version of Record online : 23 SEP 2015, DOI: 10.1111/jth.13118

  20. Circulating FVIII-specific IgG, IgA and IgM memory B cells from haemophilia A patients


    Volume 22, Issue 5, September 2016, Pages: 799–805, I. Diaz, K. Bolloré, E. Tuaillon, P. Lapalud, M. Giansily-Blaizot, J. P. Vendrell, J. F. Schved and G. Lavigne-Lissalde

    Version of Record online : 21 JUL 2016, DOI: 10.1111/hae.12958